The U.S. Food and Drug Administration (FDA) has announced new measures to make the development of biosimilar treatments faster, more efficient, and less costly. These updates simplify biosimilarity studies, reduce unnecessary clinical testing, and create clearer pathways for biosimilars to be developed as interchangeable with brand-name biologics.
According to the Biosimilars Forum, these policy changes mark an important step forward in expanding patient access to safe, effective, and affordable therapies. Julie Reed, Executive Director of the Biosimilars Forum, noted that the FDA’s actions “will accelerate safe and effective biosimilar development by eliminating unnecessary and bureaucratic inefficiencies.”
For clinicians, this could soon translate into broader therapeutic options and fewer barriers to prescribing lower-cost alternatives—particularly for biologic therapies used in gastroenterology and other specialties. By streamlining the development process and supporting interchangeability, the FDA aims to empower providers, pharmacists, and patients to make more informed decisions about effective, affordable treatment options without compromising safety or quality.
Learn more:
- FDA Press Release: FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
- Biosimilars Forum Statement: Biosimilars Forum Applauds FDA and Commissioner Dr. Marty Makary for Supporting Safe, Effective and Lower-Cost Biosimilars
- Response to HHS Press Conference: The Biosimilars Forum Thanks and Commends Trump Administration Healthcare Leaders for Supporting Lower-Cost, Safe and Effective Biosimilars
The Florida Gastroenterologic Society supports ongoing efforts that promote innovation, accessibility, and affordability in patient care, ensuring that clinicians have access to safe and effective treatment options that improve patient outcomes and lower costs.
Shared on behalf of the Biosimilars Forum’s Alliance Committee